Last reviewed · How we verify
NCT05895318: PMATAVP
Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD
trial in Post Traumatic Stress Disorder in 30 participants. Completed in 23 March 2023.
23 March 2023
Quick facts
| Lead sponsor | Albany Research Institute, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 8 August 2022 |
| Primary completion | 23 March 2023 |
| Estimated completion | 23 March 2023 |
| Sites | 1 location across United States |
Conditions studied
- Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
Sponsor
Albany Research Institute, Inc.
Who can join
18 and older, any sex, with Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this exploratory, mixed-method design study is to gather qualitative and quantitative data obtained through interviews and questionnaires with veterans who are currently enrolled at the VA for healthcare. The main question this study aims to answer is: How do veterans diagnosed with PTSD and enrolled for care at the VA understand MDMA-assisted therapy for PTSD? Using a story-completion approach, participants will be provided with a brief story starter involving a fictitious character and scenario and asking them to complete the story. Few contextual details will be offered about the character. In responding to ambiguous cues, participants are thought to project their conscious and subconscious perceptions about the phenomenon in question onto the story, a useful method for exploring stigmatized topics. The purpose of this exercise is to ascertain the participants attitudes and perceptions regarding MDMA-Assisted Therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05895318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post Traumatic Stress Disorder
Currently open trials in the same condition.
- NCT07485231 — Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD · NA · recruiting
- NCT07316088 — Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms · Phase 2 · recruiting
- NCT07227337 — Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study · NA · recruiting
- NCT06988787 — Multifaceted Intervention to Restore Resilience and Overcome Risk · NA · recruiting
- NCT06740487 — Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder · NA · recruiting
Other Albany Research Institute, Inc. trials
Trials by the same sponsor.
- NCT05616923 — Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea · Phase 1 · completed
- NCT02972996 — Blueberry Consumption and Type 2 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05895318 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Albany Research Institute, Inc.
- Last refreshed: 22 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing